97% Purity Hormone 71-58-9 Medroxyprogesterone Acetate Mifovit

Model NO.
71-58-9
Color
White or Nearly White Crystalline Powder
Volatility
Fixed
Transport Package
25kg/Drum
Specification
97%
Trademark
blue lake
Origin
Jiangxi China
Production Capacity
60 Tons Per Month
Reference Price
Please contact us for quote

Product Description



Company contact information:



Drug Description:
MPA also known as depot medroxyprogesterone acetate (DMPA) in injectable form and sold under the brand name Depo-Provera among others, is a hormonal medication of the progestin type. It is used as a method of birth control and as a part of menopausal hormone therapy. It is also used to treat endometriosisabnormal uterine bleedingabnormal sexuality in males, and certain types of cancer. The medication is available both alone and in combination with an estrogen. It is taken by mouth, used under the tongue, or by injection into a muscle or fat.


Medical use:

The most common use of MPA is in the form of DMPA as a long-acting progestogen-only injectable contraceptive to prevent pregnancy in women. It is an extremely effective contraceptive when used with relatively high doses to prevent ovulation. MPA is also used in combination with an estrogen in menopausal hormone therapy in postmenopausal women to treat and prevent menopausal symptoms such as hot flashes, vaginal atrophy, and osteoporosis.It is used in menopausal hormone therapy specifically to prevent endometrial hyperplasia and cancer that would otherwise be induced by prolonged unopposed estrogen therapy in women with intact uteruses. In addition to contraception and menopausal hormone therapy, MPA is used in the treatment of gynecological and menstrual disorders such as dysmenorrhea, amenorrhea, and endometriosis.Along with other progestins, MPA was developed to allow for oral progestogen therapy, as progesterone (the progestogen hormone made by the human body) could not be taken orally for many decades before the process of micronization was developed and became feasible in terms of pharmaceutical manufacturing.
DMPA reduces sex drive in men and is used as a form of chemical castration to control inappropriate or unwanted sexual behavior in those with paraphilias or hypersexuality, including in convicted sex offenders.DMPA has also been used to treat benign prostatic hyperplasia, as a palliative appetite stimulant for cancer patients, and at high doses (800 mg per day) to treat certain hormone-dependent cancers including endometrial cancer, renal cancer, and breast cancer.MPA has also been prescribed in feminizing hormone therapy for transgender women due to its progestogenic and functional antiandrogenic effects. It has been used to delay puberty in children with precocious puberty but is not satisfactory for this purpose as it is not able to completely suppress puberty.DMPA at high doses has been reported to be definitively effective in the treatment of hirsutism as well.
Though not used as a treatment for epilepsy, MPA has been found to reduce the frequency of seizures and does not interact with antiepileptic medications. MPA does not interfere with blood clotting and appears to improve blood parameters for women with sickle cell anemia. Similarly, MPA does not appear to affect liver metabolism, and may improve primary biliary cirrhosis and chronic active hepatitis. Women taking MPA may experience spotting shortly after starting the medication but is not usually serious enough to require medical intervention. With longer use amenorrhea (absence of menstruation) can occur as can irregular menstruation which is a major source of dissatisfaction, though both can result in improvements with iron deficiency and risk of pelvic inflammatory disease and often do not result in discontinuation of the medication.

97% Purity Hormone 71-58-9 Medroxyprogesterone Acetate Mifovit



 

Property NameProperty ValueReference
Molecular Weight386.5Computed by PubChem 2.1 (PubChem release 2023.05.07)
XLogP34.1Computed by XLogP3 3.0 (PubChem release 2023.05.07)
Hydrogen Bond Donor Count0Computed by Cactvs 3.4.8.18 (PubChem release 2023.05.07)
Hydrogen Bond Acceptor Count4Computed by Cactvs 3.4.8.18 (PubChem release 2023.05.07)
Rotatable Bond Count3Computed by Cactvs 3.4.8.18 (PubChem release 2023.05.07)
Exact Mass386.24570956Computed by PubChem 2.1 (PubChem release 2023.05.07)
Monoisotopic Mass386.24570956Computed by PubChem 2.1 (PubChem release 2023.05.07)
Heavy Atom Count28Computed by PubChem
Complexity767Computed by Cactvs 3.4.8.18 (PubChem release 2023.05.07)
Isotope Atom Count0Computed by PubChem
Defined Atom Stereocenter Count7Computed by PubChem
Undefined Atom Stereocenter Count0Computed by PubChem
Defined Bond Stereocenter Count0Computed by PubChem
Undefined Bond Stereocenter Count0Computed by PubChem
Covalently-Bonded Unit Count1Computed by PubChem
Compound Is CanonicalizedYesComputed by PubChem (release 2023.05.07)

 



company (established in July 2000)

 
Strict product testing, professional expertise, professional equipment to ensure product qualification and configuration
97% Purity Hormone 71-58-9 Medroxyprogesterone Acetate Mifovit

 
 
 
Professional protective equipment and protective buildings to ensure production safety and stabilize the production line
 
97% Purity Hormone 71-58-9 Medroxyprogesterone Acetate Mifovit



 
Professional front-line workers, proficient in operating various equipment. Regular training to learn new products and new technologies
 
97% Purity Hormone 71-58-9 Medroxyprogesterone Acetate Mifovit




 
Ensure employees have healthy diet, strengthen physical exercise, provide mental health help, provide employees with a high-quality rest environment, and provide the best protection for employees of large enterprises
97% Purity Hormone 71-58-9 Medroxyprogesterone Acetate Mifovit












 

 

PNEUTEC.IT, 2023